Document Detail

A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma.
MedLine Citation:
PMID:  14730237     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: alpha-Interferon is associated with numerous cutaneous side effects, but the accurate incidence of these complications is not clearly known. OBJECTIVES: A prospective study was designed to evaluate the incidence and clinical pattern of cutaneous side effects in a cohort of patients receiving adjuvant therapy with low-dose interferon for malignant melanoma. MATERIAL AND METHODS: A cohort of 33 patients with stage IIA and IIB melanoma treated with low-dose alpha-interferon (3 MIU 3 times a week for 18 months) were prospectively enrolled in a single-center study. The patients responded to a questionnaire on their medical history and were systematically examined for any cutaneous lesions before treatment and every 3 months afterwards. RESULTS: 29/33 patients (87%) experienced 1 or more cutaneous side effects. The most frequent was hair loss and occurred in 16 cases (48.4%). Hair discoloration was noted in 6 cases (18%). Eczematous reactions at injection sites or at remote sites were observed in 13 patients (39%). Pruritus occurred in 10 cases (30%). Xerostomia, Raynaud's phenomenon or livedo reticularis were observed in 10 patients, associated with an increase in circulating autoantibody titer in 2 cases. Some rare side effects were observed: urticaria (1 case) or angioedema (1 case), worsening of preexisting seborrheic dermatitis (3 cases), herpetic recurrence (2 cases), pityriasis versicolor (1 case), worsening of recurrent buccal aphthous ulcer (1 case) and vitiligo (1 case). CONCLUSION: Cutaneous adverse events during adjuvant immunotherapy of melanoma with low-dose alpha-interferon seem to be frequent but do not result in treatment discontinuation. A good awareness of these side effects may be useful for a more accurate survey and clinical management of patients receiving this treatment.
B Guillot; L Blazquez; D Bessis; O Dereure; J J Guilhou
Related Documents :
8884107 - Interferon-alpha therapy for hepatitis c virus recurrence after liver transplantation: ...
15759817 - A randomized, controlled, clinical study of thymosin alpha-1 versus interferon-alpha in...
8314497 - A controlled trial of high dose interferon, alone and after prednisone withdrawal, in t...
1386907 - A successful two-step integrated protocol of anti-hbv vaccination in chronic uremia.
19963247 - Influence of detrusor overactivity on storage symptoms following potassium-titanyl-phos...
18773987 - Safety of drug-eluting stents in patients with left ventricular dysfunction undergoing ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Dermatology (Basel, Switzerland)     Volume:  208     ISSN:  1018-8665     ISO Abbreviation:  Dermatology (Basel)     Publication Date:  2004  
Date Detail:
Created Date:  2004-01-19     Completed Date:  2004-06-08     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9203244     Medline TA:  Dermatology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  49-54     Citation Subset:  IM    
Copyright Information:
Copyright 2004 S. Karger AG, Basel
Service de Dermatologie, Hôpital Saint-Eloi, CHU de Montpellier, Montpellier, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects*,  therapeutic use
Head and Neck Neoplasms / drug therapy*
Interferon-alpha / adverse effects*,  therapeutic use
Melanoma / drug therapy*
Middle Aged
Prospective Studies
Pruritus / chemically induced
Skin Diseases / chemically induced*
Xerostomia / chemically induced
Reg. No./Substance:
0/Antineoplastic Agents; 0/Interferon-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis.
Next Document:  Single-dose fluconazole versus itraconazole in pityriasis versicolor.